Literature DB >> 21816955

Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.

Horace T B Ho1, Yongmei Pan, Zhiyi Cui, Haichuan Duan, Peter W Swaan, Joanne Wang.   

Abstract

Plasma membrane monoamine transporter (PMAT) is a new polyspecific transporter that interacts with a wide range of structurally diverse organic cations. To map the physicochemical descriptors of cationic compounds that allow interaction with PMAT, we systematically analyzed the interactions between PMAT and three series of structural analogs of known organic cation substrates including phenylalkylamines, n-tetraalkylammonium (n-TAA) compounds, and β-carbolines. Our results showed that phenylalkylamines with a distance between the aromatic ring and the positively charged amine nitrogen atom of ∼6.4 Å confer optimal interactions with PMAT, whereas studies with n-TAA compounds revealed an excellent correlation between IC(50) values and hydrophobicity. The five β-carbolines that we tested, which possess a pyridinium-like structure and are structurally related to the neurotoxin 1-methyl-4-phenylpyridinium, inhibited PMAT with high affinity (IC(50) values of 39.1-65.5 μM). Cytotoxicity analysis further showed that cells expressing PMAT are 14- to 15-fold more sensitive to harmalan and norharmanium, suggesting that these two β-carbolines are also transportable substrates of PMAT. We then used computer-aided modeling to generate qualitative and quantitative three-dimensional pharmacophore models on the basis of 23 previously reported and currently identified PMAT inhibitors and noninhibitors. These models are characterized by a hydrogen bond donor and two to three hydrophobic features with distances between the hydrogen bond donor and hydrophobic features ranging between 5.20 and 7.02 Å. The consistency between the mapping results and observed PMAT affinity of a set of test compounds indicates that the models performed well in inhibitor prediction and could be useful for future virtual screening of new PMAT inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21816955      PMCID: PMC3199987          DOI: 10.1124/jpet.111.184036

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

Review 1.  Molecular and cellular physiology of renal organic cation and anion transport.

Authors:  Stephen H Wright; William H Dantzler
Journal:  Physiol Rev       Date:  2004-07       Impact factor: 37.312

2.  Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2).

Authors:  Mark J Dresser; Guangqing Xiao; Maya K Leabman; Andrew T Gray; Kathleen M Giacomini
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

3.  Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.

Authors:  R Kekuda; P D Prasad; X Wu; H Wang; Y J Fei; F H Leibach; V Ganapathy
Journal:  J Biol Chem       Date:  1998-06-26       Impact factor: 5.157

4.  Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization.

Authors:  J Wang; S F Su; M J Dresser; M E Schaner; C B Washington; K M Giacomini
Journal:  Am J Physiol       Date:  1997-12

Review 5.  Isoquinoline neurotoxins in the brain and Parkinson's disease.

Authors:  T Nagatsu
Journal:  Neurosci Res       Date:  1997-10       Impact factor: 3.304

6.  Cloning and characterization of two human polyspecific organic cation transporters.

Authors:  V Gorboulev; J C Ulzheimer; A Akhoundova; I Ulzheimer-Teuber; U Karbach; S Quester; C Baumann; F Lang; A E Busch; H Koepsell
Journal:  DNA Cell Biol       Date:  1997-07       Impact factor: 3.311

7.  The interaction of n-tetraalkylammonium compounds with a human organic cation transporter, hOCT1.

Authors:  L Zhang; W Gorset; M J Dresser; K M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

8.  Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.

Authors:  Alexander Storch; Yu-I Hwang; Debra A Gearhart; J Warren Beach; Edward J Neafsey; Michael A Collins; Johannes Schwarz
Journal:  J Neurochem       Date:  2004-05       Impact factor: 5.372

Review 9.  The SLC22 drug transporter family.

Authors:  Hermann Koepsell; Hitoshi Endou
Journal:  Pflugers Arch       Date:  2003-07-19       Impact factor: 3.657

10.  Ionization processes of some harmala alkaloids.

Authors:  K T Douglas; R K Sharma; J F Walmsley; R C Hider
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

View more
  12 in total

1.  Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.

Authors:  Shiro Itagaki; Vadivel Ganapathy; Horace T B Ho; Mingyan Zhou; Ellappan Babu; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2012-03-06       Impact factor: 3.922

Review 2.  Equilibrative nucleoside transporters-A review.

Authors:  Rebba C Boswell-Casteel; Franklin A Hays
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-10-19       Impact factor: 1.381

3.  Potent inhibition of human organic cation transporter 2 (hOCT2) by β-carboline alkaloids.

Authors:  David J Wagner; Haichuan Duan; Alenka Chapron; Richard W Lee; Joanne Wang
Journal:  Xenobiotica       Date:  2017-03-02       Impact factor: 1.908

Review 4.  Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.

Authors:  Avner Schlessinger; Matthew A Welch; Herman van Vlijmen; Ken Korzekwa; Peter W Swaan; Pär Matsson
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

5.  Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition.

Authors:  S Ekins; J E Polli; P W Swaan; S H Wright
Journal:  Clin Pharmacol Ther       Date:  2012-09-26       Impact factor: 6.875

6.  Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene.

Authors:  Haichuan Duan; Joanne Wang
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

7.  Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.

Authors:  Haichuan Duan; Tao Hu; Robert S Foti; Yongmei Pan; Peter W Swaan; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2015-08-18       Impact factor: 3.922

Review 8.  The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.

Authors:  J Wang
Journal:  Clin Pharmacol Ther       Date:  2016-09-19       Impact factor: 6.875

Review 9.  Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics.

Authors:  David J Wagner; Tao Hu; Joanne Wang
Journal:  Pharmacol Res       Date:  2016-06-16       Impact factor: 7.658

Review 10.  The Interaction of Organic Cation Transporters 1-3 and PMAT with Psychoactive Substances.

Authors:  Julian Maier; Marco Niello; Deborah Rudin; Lynette C Daws; Harald H Sitte
Journal:  Handb Exp Pharmacol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.